Search results for "BLAST"

showing 10 items of 2136 documents

ERGO: A pilot study of ketogenic diet in recurrent glioblastoma

2014

Limiting dietary carbohydrates inhibits glioma growth in preclinical models. Therefore, the ERGO trial (NCT00575146) examined feasibility of a ketogenic diet in 20 patients with recurrent glioblastoma. Patients were put on a low-carbohydrate, ketogenic diet containing plant oils. Feasibility was the primary endpoint, secondary endpoints included the percentage of patients reaching urinary ketosis, progression-free survival (PFS) and overall survival. The effects of a ketogenic diet alone or in combination with bevacizumab was also explored in an orthotopic U87MG glioblastoma model in nude mice. Three patients (15%) discontinued the diet for poor tolerability. No serious adverse events attri…

MaleCancer ResearchStatement (logic)medicine.medical_treatmentSalvage treatmentPilot ProjectsBioinformaticsGastroenterologyMicegliomaClinical endpoint1306 Cancer ResearchglucoseArticlesMiddle AgedCombined Modality TherapyBevacizumabTreatment OutcomeTolerabilityOncologyketogenic dietFemale2730 OncologyDiet Ketogenicmedicine.drugAdultmedicine.medical_specialtyBevacizumabMice NudeAntineoplastic Agents610 Medicine & healthMistakeRecurrent GliomaBiologyAntibodies Monoclonal HumanizedInternal medicineGliomamedicineAnimalsHumansddc:610Adverse effectAgedbusiness.industryRecurrent glioblastomaGeneral surgeryKetosisNeoplasms Experimentalmedicine.diseaseSurvival Analysis10040 Clinic for NeurologySurgeryQuality of LifeNeoplasm Recurrence LocalKetosisGlioblastomabusinessmetabolismfeasibilityKetogenic dietInternational Journal of Oncology
researchProduct

Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT‘91

2009

PURPOSE: To analyse long-term outcome and clinical prognostic factors in medulloblastoma. METHODS: We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chemotherapy (median follow-up of survivors for 10 years). RESULTS: In 187 patients with complete staging, overall survival (OS) was higher after maintenance compared to sandwich treatment for M0 (10-year OS 91% and 62%, p=0.001) and M1 patients (10-year OS 70% and 34%, p=0.020). In M2/3 disease, 10-year OS was 42% and 45%. Incomplete staging, metastases, younger age and sandwich chemotherapy were independe…

MaleCancer ResearchVincristinePediatricsmedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentAntineoplastic AgentsDrug Administration Schedulelaw.inventionMaintenance therapyRandomized controlled triallawmedicineHumansCerebellar NeoplasmsChildSurvival rateNeoplasm StagingProportional Hazards ModelsMedulloblastomaChemotherapybusiness.industryProportional hazards modelNeoplasms Second Primarymedicine.diseaseCombined Modality TherapySurvival RateClinical trialTreatment OutcomeOncologyVincristineChild PreschoolFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesMedulloblastomamedicine.drugEuropean Journal of Cancer
researchProduct

Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International society of paediatric oncology (SI…

1995

In a multicentre randomised clinical trial 364 children with biopsy proven medulloblastoma were randomly assigned to receive or not pre-radiotherapy chemotherapy. Children with total or subtotal removal of the tumour, no evidence of invasive brain stem involvement, and no evidence of metastatic disease either within or without the cranium were designated "low risk", those with gross residual tumour, evidence of invasive brain stem involvement or metastases in the central nervous system were designated "high risk". All children were prescribed 55 Gy to the tumour bearing area. "Low risk" children could be randomised to "standard" radiotherapy 35 Gy to the craniospinal axis or "reduced" dose …

MaleCancer ResearchVincristinemedicine.medical_specialtyPediatricsTime FactorsAdolescentmedicine.medical_treatmentProcarbazinelaw.inventionRandomized controlled trialRecurrenceRisk FactorslawAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineProspective StudiesCerebellar NeoplasmsChildProspective cohort studyMedulloblastomabusiness.industryInfantRadiotherapy Dosagemedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryRadiation therapyClinical trialOncologyChild PreschoolPediatrics Perinatology and Child HealthFemalebusinessCraniospinalMedulloblastomamedicine.drugMedical and Pediatric Oncology
researchProduct

Genetics of retinoblastoma: A study

1997

Abstract We have analyzed 43 families with either familial retinoblastoma (RB) (four kindreds), bilateral sporadic RB (10 individuals), or unilateral sporadic RB (29 individuals). Genetic studies focused on karyotype analysis, loss of heterozygosity of intragenic polymorphisms, and search for point mutations. We have been able to identify the genetic defect underlying the disease in eight cases. Deletions have been found in three patients with sporadic RB, two bilateral in one of which karyotyping had previously detected an interstitial deletion of chromosome 13 affecting (q13–q31) and one unilateral. Five different point mutations were responsible for three cases of bilateral sporadic RB, …

MaleCancer Researchmedicine.medical_specialtyGenetic counselingBiologymedicine.disease_causeLoss of heterozygosityGeneticsmedicineHumansPoint MutationGenes RetinoblastomaMolecular BiologyChromosome 13GeneticsMutationPolymorphism GeneticChromosomes Human Pair 13RetinoblastomaEye NeoplasmsPoint mutationRetinoblastomaCytogeneticsmedicine.diseasePedigreeKaryotypingFemaleCarcinogenesisGene DeletionCancer Genetics and Cytogenetics
researchProduct

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung ca…

2005

Purpose To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non—small-cell lung cancer treated with chemotherapy. Patients and Methods Data from 566 patients enrolled onto the phase III randomized Multicenter Italian Lung Cancer in the Elderly Study (MILES) study were analyzed. Functional status was measured as activities of daily living (ADL) and instrumental ADL (IADL). The presence of comorbidity was assessed with a checklist of 33 items; items 29 and 30 of the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 (EORTC QLQ-C30) wer…

MaleCancer Researchmedicine.medical_specialtyLung NeoplasmsActivities of daily livingHealth StatuscarcinomaVinblastineVinorelbineDeoxycytidineolder peopleQuality of lifeInstrumental activitieCarcinoma Non-Small-Cell LungInternal medicineActivities of Daily LivingAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerAgedAged 80 and overvalidationProportional hazards modelbusiness.industryQLQ-C30Age FactorsCancerVinorelbineclinical trialPrognosismedicine.diseaseGemcitabineComorbidityhumanitiescomorbidityOncologyQuartileQuality of LifePhysical therapyimpactGeriatric oncologyFemalebusinessRandomized-trialmedicine.drug
researchProduct

Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastoma—An Experience From the HIT-RE…

2013

Purpose To evaluate the efficacy of craniospinal irradiation (CSI) in the management of recurrent infant medulloblastoma after surgery and chemotherapy alone. Methods and Materials Seventeen pediatric medulloblastoma patients registered in the HIT-REZ 1997 and 2005 studies underwent CSI as salvage treatment at first recurrence. All patients had achieved complete remission after first-line treatment consisting of surgery and chemotherapy. Eleven patients showed metastatic disease at relapse. Five patients underwent surgery prior to radiation therapy, which resulted in complete resection in 1 case. In 1 patient, complete resection of the residual tumor was performed after CSI. Eleven patients…

MaleCancer Researchmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMedizinDisease-Free SurvivalCraniospinal IrradiationCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHumansRadiology Nuclear Medicine and imagingNeoplasm MetastasisChildNeoplasm StagingProportional Hazards ModelsSalvage TherapyMedulloblastomaChemotherapyUnivariate analysisRadiationBrain Neoplasmsbusiness.industryProportional hazards modelInfantRadiotherapy Dosagemedicine.disease3. Good healthSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisMultivariate AnalysisFemaleCranial IrradiationNeoplasm Recurrence LocalbusinessCraniospinal030217 neurology & neurosurgeryProgressive diseaseFollow-Up StudiesMedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-…

2004

Abstract Based on the results of combined data from three North American Phase II studies, a randomised Phase II study in the same patient population was performed, using combination chemotherapy with estramustine phosphate (EMP) and vinblastine (VBL) in hormone refractory prostate cancer patients. In all, 92 patients were randomised into a Phase II study of oral EMP (10 mg kg day continuously) or oral EMP in combination with intravenous VBL (4 mg m(2) week for 6 weeks, followed by 2 weeks rest). The end points were toxicity and PSA response in both groups, with the option to continue the trial as a Phase III study with time to progression and survival as end points, if sufficient responses…

MaleCancer Researchmedicine.medical_specialtyUrologyAdministration OralPhases of clinical researchVinblastineMetastasisClinicalProstate cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousSurvival analysishormone-escaped prostate cancerEMP/VBL vs EMPbusiness.industryProstatic NeoplasmsCombination chemotherapyProstate-Specific Antigenmedicine.diseaseSurvival AnalysisPhase IISurgeryVinblastineProstate-specific antigenOncologyDrug Resistance NeoplasmDisease ProgressionEstramustineEstramustinebusinessmedicine.drug
researchProduct

Chromosome 5 abnormalities in acute lymphoblastic leukemia

1991

Abstract We report two cases of acute lymphoblastic leukemia with involvement of chromosome 5. One of them showed a del(5)(q13q33) in a 5-year-old boy who had previously received antineoplastic chemotherapy for an L1-ALL that had been diagnosed nine months before. The other one showed a t(5;7)(q12–13;q36) together with a t(8;14)(q24;q32) and a der(1) in a 66-year-old man with an L3-ALL. Both chromosome 5 aberrations are interpreted as evolutionary events. In the first case, it was secondary to chemotherapy treatment; in the second, an evolutionary chromosome rearrangement, considering the translocation between chromosomes 8 and 14 as the primary cytogenetic event.

MaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentLymphoblastic LeukemiaChromosome DisordersChromosomal translocationChromosomal rearrangementBiologyAcute lymphocytic leukemiaAntineoplastic chemotherapyGeneticsmedicineHumansMolecular BiologyChromosome AberrationsChemotherapyCytogeneticsChromosomePrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseChromosome BandingChild PreschoolKaryotypingImmunologyCancer researchChromosomes Human Pair 5Cancer Genetics and Cytogenetics
researchProduct

Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck

1997

BACKGROUND The combination of vinorelbine (VNR), cisplatin (CDDP), and 5-fluorouracil (5-FU) has previously been shown to be active in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCHNC). This multicenter Phase II study was carried out with the aim of evaluating the effectiveness of this combination in patients with previously untreated, unresectable locally advanced SCHNC. METHODS Sixty patients with previously untreated, unresectable SCHNC were treated with CDDP 80 mg/m2 on Days 1, 5-FU 600 mg/m2 as a 4-hour infusion on Days 2-5, and VNR 25 mg/m2 iv bolus on Days 2 and 8. There were 15 patients with laryngeal carcinoma, 19 patients with oropharyngeal carcinoma…

MaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchVinblastineVinorelbineGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansAgedChemotherapybusiness.industryInduction chemotherapyVinorelbineMiddle Agedmedicine.diseaseSurgeryRegimenOncologyEpidermoid carcinomaChemotherapy AdjuvantHead and Neck NeoplasmsFluorouracilCarcinoma Squamous CellFemaleRadiotherapy AdjuvantFluorouracilCisplatinbusinessmedicine.drugCancer
researchProduct

Unique pharmacology of KAR-2, a potential anti-cancer agent: absorption modelling and selective mitotic spindle targeting.

2008

Abstract Bis-indols are a large group of the anti-cancer agents, which effectively arrest the uncontrolled division of the cancerous cells. Their use in clinical chemotherapy is still limited because of: (i) the non-specific targeting of the mitotic cells; (ii) low bioavailability of the drugs. KAR-2 has been identified as a tubulin binding agent which displays significantly lower cytotoxicity but favourable anti-cancer potency than its mother molecule, vinblastine. The objective of this paper, on one hand, was to show that the human intestinal epithelial Caco-2 cells, used for pharmacokinetic studies display distinct sensitivity against KAR-2 and vinblastine due to their distinct targeting…

MaleCell divisionStereochemistryPharmaceutical ScienceBiological Transport ActiveSpindle ApparatusBiologyVinblastinePermeabilityInjectionsmedicineAnimalsHumansATP Binding Cassette Transporter Subfamily B Member 1Rats WistarCytotoxicityMitosisChromatography High Pressure LiquidModels StatisticalAntineoplastic Agents PhytogenicIn vitroSpindle apparatusVinblastineRatsSpectrometry FluorescenceIntestinal AbsorptionTubulin Binding AgentBiophysicsInterphaseCaco-2 CellsAlgorithmsmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct